Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease

CNS Drugs

Volumn 5, Issue 4, 1996, Pages 293-310

  Patel, Toshal R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; BQ 610; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO ALLO ISOLEUCYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N ACETYL 10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLGLYCYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; PHOSPHORAMIDON;

BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR DISEASE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUBARACHNOID HEMORRHAGE;

EID: 0030002905     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605040-00007     Document Type: Review

References (178)

1. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5
2. Furchgott R, Zawadski J. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6
3. Hickey KA, Rubanyi GM, Paul RJ, et al. Characterisation of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248: C550-6
4. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5
5. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-7
6. Doherty AM. Endothelin: a new challenge. J Med Chem 1992; 35: 1493-508
7. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins. Circulating plasma levels and presence in other biologic fluids. Lab Invest 1993; 68: 600-28
8. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol Rev 1994; 46: 325-415
9. Opgenorth TJ, Wu-Wong JR, Shiosaki K. Endothelin converting enzymes. FASEB J 1992; 6: 2653-9
10. Schmidt M, Kroger B, Jacob E, et al. Molecular characterisation of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett 1995; 356: 238-43
11. Deschepper CF, Houweling AD, Picard S. The membranes of cultured rat brain astrocytes contain endothelin-converting enzyme activity. Eur J Pharmacol 1995; 275: 61-6
12. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2
13. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of cDNA encoding a non isopeptide selective subtype of the endothelin receptor. Nature 1990; 348: 732-5
14. Masaki T, Vane J, Vanhoutte PM. International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 1994; 46: 137-42
15. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterisation of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanocytes. J Biol Chem 1993; 268: 19126-33
16. Gandhi CR, Berkowitz DE, Watkins WD. Endothelins: biochemistry and pathophysiologic actions. Anaesthesiology 1994; 80: 892-905
17. Fukuroda T, Noguchi K, Tsuchida S, et al. Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem Biophys Res Comun 1990; 172: 390-5
18. Clozel M, Gray GA, Breu V, et al. The endothelin ETB receptor mediates vasodilatation and vasoconstriction in vivo. Biochem Biophys Res Commun 1992; 186: 867-73
19. Shetty SS, Okada T, Webb RL, et al. Functionally distinct endothelin ETB receptor in vascular endothelium and smooth muscle. Biochem Biophys Res Commun 1993; 191: 459-64
20. Seo BG, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89: 1203-8
21. Warner TD, Allcock GH, Corder R, et al. Use of the endothelin antagonists BQ-123 and PD-142893 to reveal 3 endothelin receptors mediating smooth-muscle contraction and the release of EDRF. Br J Pharmacol 1993; 110: 777-82
22. Bax W, Egbert B, Saxena P. Heterogeneity of endothelin/ sarafotoxin receptors mediating contraction of the human isolated saphenous vein. Eur J Pharmacol 1993; 239: 267-8
23. Fukuroda T, Ozaki S, Ihara M, et al. Synergistic inhibition by BQ123 and BQ788 of endothelin-1 induced contractions of the rabbit pulmonary artery. Br J Pharmacol 1994; 113: 336-8
24. Cardell LO, Udmann R, Edvinsson L. A novel ETA receptor antagonist FR139317 inhibits endothelin induced contractions of guinea pig pulmonary arteries, hut not trachea. Br J Pharmacol 1993; 108: 448-52
25. + channels. Eur J Pharmacol 1992; 219: 355-60
26. Lin WW, Lee CY. Biphasic effects of endothelin in the guinea pig ileum. Eur J Pharmacol 1990; 176: 57-62
27. Kurihara H, Yoshizumi M, Sugiyama T, et al. Transforming growth factor-β stimulates the expression endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989; 159: 1435-40
28. Clozel M, Clozel J-P. Effects of endothelin on regional cerebral blood flow in squirrel monkeys. J Pharmacol Exp Ther 1989; 250: 1125-31
29. Gellai M, Jugus M, Fletcher T, et al. Reversal of post-ischaemic acute renal failure with a selective ETA receptor antagonist in the rat. J Clin Invest 1994; 93: 900-6
30. Wallace JL, Keenan CM, MacNaughton WK, et al. Comparison of the effects of endothelin-1 and endothelin-3 on the rat stomach. Eur J Pharmacol 1989; 167: 41-7
31. Godfraind T, Mennig D, Morel N, et al. Effect of endothelin-1 on calcium channel gating by agonists in vascular smooth muscle. J Cardiovasc Pharmacol 1989; 13 Suppl. 5: S112-7
32. Egashima K, Pipers FS, Rush JE, et al. Effects of calcium channel blockers on coronary vasoconstriction induced by endothelin-1 in closed chest pigs. J Am Coll Cardiol 1990; 16: 1296-303
33. Encabo A, Ferrer M, Marin J, et al. Vasoconstrictive responses elicited by endothelin in bovine cerebral arteries. Gen Pharmacol 1992; 23: 263-7
34. Fozard JR, Part ML. The role of nitric oxide in the regional vasodilator effects of endothelin-1 in the rat. Br J Pharmacol 1992; 105: 744-50
35. Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological of a potent and selective endothelin-B receptor antagonist BQ788. Proc Natl Acad Sci USA 1994; 91: 4892-6
36. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-73
37. Hardebo JE, Kahrstrom J, Owman C, et al. Endothelin is a potent constrictor of human intracranial arteries and veins. Blood Vessels 1989; 26: 249-53
38. Saito A, Shiba R, Kimura S, et al. Vasoconstrictor response of large cerebral arteries of cats to endothelin, an endothelium derived vasoactive peptide. Eur J Pharmacol 1989; 162: 353-8
39. Saito A, Shiha R, Yanagisawa M, et al. Endothelins: vasoconstrictor effects and localisation in canine cerebral arteries. Br J Pharmacol 1991; 103: 1129-35
40. Feger GI, Schilling L, Ehrenreich H, et al. Endothelin-induced contraction and relaxation of isolated rat basilar artery: effect of BQ-123. J Cereb Blood Flow Metab 1994; 14: 845-52
41. Salom JB, Torregrosa G, Alborch E. Endothelins and the cerebral circulation. Cerebrovasc Brain Metab Rev 1995; 7: 131-52
42. Salom J, Torregrossa G, Barbera M, et al. Endothelin receptors mediating contraction in goat cerebral arteries. Br J Pharmacol 1993; 109: 826-30
43. Adner M, You J, Edvinsson L. Characterisation of endothelin-A receptors in the cerebral circulation. Neuroreport 1993; 4: 441-3
44. Willette R, Sauermelch C. Abluminal effects of endothelin in cerebral microvasculature assessed by laser doppler flowmetry. Am J Physiol 1990; 259: H1688-93
45. Faraci FM. Effects of endothelin and vasopressin on cerebral blood vessels. Am J Physiol 1989; 257: H799-803
46. Robinson MJ, McCulloch J. Contractile responses to endothelin in feline cortical vessels in situ. J Cereb Blood Flow Metab 1990; 10: 265-89
47. Yoshimoto S, Ishizaki Y, Kurihara M, et al. Cerebral microvessel endothelium is producing endothelin. Brain Res 1990; 580: 283-5
48. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-8
49. Mima T, Yanagisawa M, Shigeno T, et al. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 1989; 20: 1553-6
50. Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non selective type of endothelin receptor on vascular endothelium and its linkage to vasodilatation. FEBS Lett 1990; 282: 103-6
51. Davenport AP, Nunez DJ, Brown MJ. Localisation of binding sites for iodinated endothelin and sarafotoxin peptides in mammalian tissues using quantitative receptor autoradiography. Eur J Pharmacol 1990; 183: 2153
52. Patel TR, McAuley MA, McCulloch J. Significance of endothelin ETA and ETB receptors in cerebral arterioles in situ [abstract]. J Cereb Blood Flow Metab 1995; 15 Suppl. 1: S542
53. Yu JCM, Pickard JD, Davenport AP. Characterisation of endothelin receptors in cultured human cerebral vascular smooth muscle cells [abstract]. Br J Pharmacol 1995; 114 Suppl.: 195P
54. Schilling L, Feger GI, Ehrenreich H, et al. Endothelin-3 induced relaxation of isolated rat basilar artery is mediated by an endothelial ETB type endothelin receptor. J Cereb Blood Flow Metab 1995; 15: 699-705
55. Kobayashi H, Hayashi M, Kobayashi S, et al. Cerebral vasospasm and vasoconstriction caused by endothelin. Neurosurgery 1991; 28: 673-9
56. McCarron RM, Wang L, Stanimirovic DB, et al. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett 1993; 156: 31-4
57. Durieu-Trautmann O, Federici C, Creminon C, et al. Nitric oxide and endothelin secretion by brain microvessel endothelial cells: regulation by cyclic nucleotides. J Cell Physiol 1993; 155: 104-11
58. Frelin C, Ladoux A, Marsault R, et al. Function of vasoactive factors in the cerebral microcirculation. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S94-6
59. Foley PL, Caner HH, Kassell NF, et al. Reversal of subarachnoid hemorrhage-induced vasoconstriction with an endothelin receptor antagonist. Neurosurgery 1994; 34: 108-13
60. McAuley MA, Patel TR, Galbraith S, et al. Endothelin and its pathophysiological role in the cerebral circulation. In: Krieglstein J, Oberpichler-Schwenk H, editors. Pharmacology of cerebral ischaemia. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1994: 511-24
61. Patel TR, McAuley MA, McCulloch J. Effects on feline pial arterioles in situ of bosentan, a non peptide endothelin receptor antagonist. Eur J Pharmacol 1994; 260: 65-71
62. Patel TR, McAuley MA, Doherty AM, et al. Pharmacological characterisation of peptide and non-peptide endothelin antagonists in cerebral arterioles in situ [abstract]. J Cereb Blood Flow Metab 1995; 15 Suppl. 1: S535
63. Zuccarrello M, Lewis AI, Rapoport RM. Endothelin ETA and ETB receptors in subarachnoid hemorrhage-induced cerebral vasospasm. Eur J Pharmacol 1994; 259: R1-2
64. Kitazono T, Heistad DD, Faraci FM. Activation of endothelin B receptors produces dilatation of the basilar artery in vivo [abstract]. Circulation 1993; 88 Suppl.: 1-170
65. Kobari M, Fukuuchi Y, Tomita M, et al. Dilatation of cerebral microvessels mediated by endothelin ETB receptor and nitric oxide in cats. Neurosci Lett 1994; 176: 157-60
66. Niwa M, Kawaguichi T, Himeno T, et al. Specific binding sites for 1251-endothelin-1 in the porcine and human spinal cord. Eur J Pharmacol 1992; 225: 281-9
67. Jones C, Hiley C, Pelton J, et al. Autoradiographic visualisation of the binding sites for 1251-endothelin in rat and human brain. Neurosci Lett 1989; 97: 276-9
68. Giaid A, Gibson SJ, Ibrahim NBN, et al. Endothelin-1 an endothelium derived peptide is expressed in neurones of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci USA 1989; 86: 7634-8
69. MacCumber M, Ross C, Snyder S. Endothelin in brain: receptor, mitogenesis and biosynthesis in glial cells. Proc Natl Acad Sci USA 1990; 87: 2359-63
70. Greenberg DA, Chan J, Sampson HA. Endothelins and the nervous-system. Neurology 1992; 42: 25-31
71. Koseki C, Imai M, Hirata Y, et al. Autoradiographic distribution in rat tissue of binding sites for endothelin: a neuropeptide? Am J Physiol 1989; 256: R858-66
72. Kurihara H, Ochi A, Kawaguchi T, et al. Localisation and characterisation of endothelin receptors in human gliomas: a growth factor? Neurosurgery 1990; 27: 275-81
73. Nambi P, Pullen M, Feuerstein GZ. Identification of endothelin receptors in various regions of the rat brain. Neuropeptides 1990; 16: 195-9
74. + exchange in brain capillary endothelial cells via a high affinity endothelin-3 receptor that is not coupled to phospholipase C. J Biol Chem 1991; 266: 5925-8
75. Lee ME, Delamonte SM, Ng SC, et al. Expression of the potent vasoconstrictor endothelin in the human central nervous system. J Clin Invest 1990; 86: 141-7
76. Lysko PG, Feuerstein GZ, Pullen M, et al. Identification of endothelin receptors in cultured cerebellar neurones. Neuropeptides 1991; 18: 83-6
77. Fuxe K, Kurosawa N, Cintra A, et al. Involvement of local ischaemia in endothelin-1 induced lesions of the neostriatum of the anaesthetised rat. Exp Brain Res 1992; 88: 131-9
78. Marsault R, Vigne P, Breittmayer J-P, et al. Astrocytes are targets for endothelins and sarafotoxins. J Neurochem 1990; 54: 2142-4
79. Ehrenreich H, Kehrl J, Anderson R, et al. A vasoactive peptide, endothelin-3 is produced by and specifically binds to primary astrocytes. Brain Res 1991; 538: 54-8
80. Federici C, Camoin L, Creminon C, et al. Cultured astrocytes release a factor that decreases endothelin-1 secretion by brain microvessel endothelial cells. J Neurochem 1995; 64: 1008-15
81. Levin ER, Isackson PJ, Hu RM. Endothelin receptors on cultured fetal rat diencephalic glia. J Neurochem 1992; 58: 659-66
82. Ladenheim R, Lacroix I, Foignant-Chaverot N, et al. Endothelins stimulate c-fos and nerve growth factor expression in astrocytes and astrocytoma. J Neurochem 1993; 60: 260-6
83. Siren AL, Feuerstein GZ. Haemodynamic effects of endothelin after systemic and central nervous system administration in the conscious rat. Neuropeptides 1989; 14: 231-6
84. Ferguson AV, Smith P. Cardiovascular responses induced by endothelin microinjection into area postrema. Regul Pept 1990; 27: 75-85
85. Macrae IM, Robinson M, McAuley M, et al. Effects of intracisternal endothelin-1 injection on blood flow to the lower brain stem. Eur J Pharmacol 1991; 203: 85-91
86. Gross PM, Beninger RJ, Shaver SW, et al. Metabolic and neuroanatomical correlates of barrel-rolling and oculoclonic convulsions induced by intraventricular endothelin-1: a novel peptidergic signalling mechanism in visuovestibular and oculomotor regulation? Exp Brain Res 1994; 95: 397-408
87. Gross PM, Weaver DF, Wainman DS, et al. Potent metabolic stimulation of septal gray and cerebral white matter in vivo by intraventricular endothelin and nitric oxide. Biochem Biophys Res Commun 1993; 190: 975-81
88. Berrino L, D'Amico M, Pizziruso A, et al. Excitatory amino acids modulate the cardiovascular effects of endothelin-1 in the periaqueductal gray area [abstract]. Br J Pharmacol 1994; 111 Suppl.: 173P
89. Ihara M, Fukuroda T, Saeki T, et al. An endothelin receptor (ETA) antagonist isolated from streptomyces misakiensis. Biochem Biophys Res Commun 1991; 178: 132-7
90. Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists for the ETA receptor. Life Sci 1992; 50: 247-55
91. Cody WL, Doherty AM, He JX, et al. The rational design of a highly potent combined ETA and ETB receptor antagonist (PD145065) and related analogues. Med Chem Res 1993; 3: 154-62
92. Itoh S, Sasaki T, Ide K, et al. A novel endothelin ETA receptor antagonist BQ485 and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 1993; 195: 969-75
93. Sogabe K, Nirei H, Shoubo M, et al. Pharmacological profile of FR139317, a novel potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1993; 264: 1040-6
94. 125I] BQ3020 selective for endothelin (ETB) receptors. Life Sci 1992; 51: 47-52
95. 11,15] endothelin-1 (8-21), IRL-1620, for the ETB receptor. Biochem Biophys Res Commun 1992; 184: 953-9
96. 15] endothelin-1 (11-21). FEBS Lett 1992; 311: 12-6
97. Watanabe T, Awane Y, Ikeda S, et al. Pharmacology of a non selective ETA and ETB receptor antagonist TAK044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol 1995; 114: 949-54
98. Doherty AM, Patt WC, Edmunds JJ, et al. Discovery of a novel series of orally active non peptide endothelin-A (ETA) receptor selective antagonists. J Med Chem 1995; 38: 1259-63
99. Webb ML, Bird JE, Liu ECK, et al. BMS182874 is a selective non peptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther 1995; 272: 1124-34
100. Clozel M, Breu V, Gray GA, et al. Pharmacological characterisation of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-35
101. Clozel M, Breu V, Burri K, et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759-63
102. Williams DL, Nolan NA, O'Brein JA, et al. Pharmacology of L754142, a potent, orally active nonpeptidyl endothelin antagonist [abstract no. C46]. Proceedings of the 4th International Conference on Endothelin; 1995 Apr 23-26: London
103. Walsh TF, Fitch KJ, Toupence RB, et al. SAR and pharmacology of L751281, a member of a new series of non peptide ET antagonists [abstract no. C45]. Proceedings of the 4th International Conference on Endothelin; 1995 Apr 23-26: London
104. Nambi P, Elshourbagy NA, Wu H-L, et al. Non peptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human ETA and ETB receptors. J Pharmacol Exp Ther 1994; 271: 755-61
105. Lago MA, Cousins RD, Gao A, et al. Rational design and synthesis of potent non peptide ET receptor antagonists [abstract no. C44]. Proceedings of the 4th International Conference on Endothelin: 1995 Apr 23-26; London
106. The blood-brain barrier. In: Edvinsson L, MacKenzie ET, McCulloch J, editors. Cerebral blood flow and metabolism. New York: Raven Press, 1993: 142-52
107. Ermisch A, Brust P, Kretzschmar R, et al. Peptides and blood brain barrier transport. Physiol Rev 1993; 73: 489-527
108. Clozel M, Watanabe H. BQ123, a peptidic endothelin ETA receptor antagonist prevents the early vasospasm following subarachnoid haemorrhage after intracisternal but not intravenous injection. Life Sci 1993; 52: 825-34
109. Ohlstein EH, Nambi P, Douglas SA, et al. SB209670, a rationally designed potent non peptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994; 91: 8052-6
110. Fukami T, Hayama T, Amano Y, et al. Aminophosphonate endothelin converting enzyme inhibitors: potency enhancing and selectivity improving modifications of phosphoramidon. Bioorg Med Chem Lett 1994; 4: 1257-62
111. De Lombaert S, Ghai RD, Jeng AY, et al. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem Biophys Res Commun 1995; 204: 407-12
112. Duverger D, Viossat I, Chapelat M, et al. Effects of phosphoramidon on immunoreactive ET-1 contents in brain and volume of infarctus in MCA-occluded rat [abstract]. J Cereb Blood Flow Metab 1993; 13 Suppl. 1: S194
113. Brunner F, du Toit EF, Opie LH. Endothelin release during ischaemia and reperfusion of isolated perfused rat hearts. J Mol Cell Cardiol 1992; 24: 1291-305
114. Seifert V, Loffler B-M, Zimmermann M, et al. Endothelin concentrations in patients with aneurysmal subarachnoid haemorrhage. J Neurosurg 1995; 82: 55-62
115. Shirakami G, Magaribuchi T, Shingu K, et al. Changes of endothelin concentration in cerebrospinal fluid and plasma of patients with aneurysmal subarachnoid haemorrhage. Acta Anaesthesiol Scand 1994; 38: 457-61
116. Ehrenreich H, Lange M, Near KA, et al. Long-term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal-fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med 1992; 192: 257-68
117. Suzuki R, Masaoka H, Hirata Y, et al. The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1992; 77: 96-100
118. Gaetani P, Rodriguez y Baena R, Grignani G, et al. Endothelin and aneurysmal subarachnoid haemorrhage: a study of subarachnoid cisternal cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1994; 57: 66-72
119. Kraus GE, Bucholz RD, Yoon K-W, et al. Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurosurgical patients: a clinical study and literature review. Surg Neurol 1991; 35: 20-9
120. Hirata Y, Matsunaga T, Ando K, et al. Presence of plasma endothelin-1-like immunoreactivity in human cerebrospinal fluid. Biochem Biophys Res Commun 1990; 166: 1274-8
121. Ziv I, Heminger G, Djaldetti R, et al. Increased plasma endothelin-1 in acute ischaemic stroke. Stroke 1992; 23: 1014-6
122. Gang-Zhi W, Jin Z, Shu-Li S, et al. Increased plasma endothelin-1 concentration in patients with acute cerebral infarction and actions of endothelin-1 on pial arterioles of rat. Chin Med J 1993; 106: 917-21
123. Barone FC, Globus MY-T, Price WJ, et al. Endothelin levels increase in rat focal and global ischaemia. J Cereb Blood Flow Metab 1994; 14: 337-42
124. Giuffrida R, Bellomo M, Polizzi G, et al. Ischaemia-induced changes in the immunoreactivity for endothelin and other vasoactive peptides in the brain of the mongolian gerbil. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S41-4
125. Yamashita K, Niwa M, Kataoka Y, et al. Microglia with an endothelin ETB receptor aggregate in rat hippocampus CA1 subfields following transient forebrain ischaemia. J Neurochem 1994; 63: 1042-51
126. Willette RN, Ohlstein EH, Pullen M, et al. Transient forebrain ischaemia alters acutely endothelin receptor density and immunoreactivity in gerbil brain. Life Sci 1992; 52: 35-40
127. Duverger D, Viossat I, Chapelat M, et al. Focal ischaemia in the rat: measurement of brain tissue endothelin [in French]. Circ Metab Cerveau 1992; 9: 85-93
128. Lustig HS, Chan J, Greenberg DA. Comparative neurotoxic potential of glutamate endothelins and platelet activating factor in cerebral cortical cultures. Neurosci Lett 1992; 139: 15-8
129. Nikolov R, Rami A, Krieglstein J. Endothelin-1 exacerbates focal cerebral ischaemia without exerting neurotoxic action in vitro. Eur J Pharmacol 1993; 248: 205-8
130. Robinson MJ, Macrae IM, Todd M, et al. Reduction of local cerebral blood flow to pathological levels by endothelin-1 applied to the middle cerebral artery in the rat. Neurosci Lett 1990; 118: 269-72
131. Macrae IM, Robinson MJ, Graham DI, et al. Endothelin-1-induced reductions in cerebral blood flow: dose dependency, time course and neuropathological consequences. J Cereb Blood Flow Metab 1993; 13: 276-87
132. Sharkey J, Ritchie IM, Kelly PAT. Perivascular microapplication of endothelin-1: a new model of focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1993; 13: 865-71
133. Malek A, Izumo S. Physiological fluid shear stress causes the down regulation of ET-1 mRNA in bovine aortic endothelium. Am J Physiol 1992; 263: C389-96
134. Ohlstein EH, Storer B. Endothelin may be the mediator of oxyhaemoglobin-induced cerebral vasospasm. Circulation 1992; 86: 288-90
135. Tippler B, Herbst C, Simmet T. Evidence for the formation of endothelin by lysed red blood cells from endogenous precursor. Eur J Pharmacol 1994; 271: 131-9
136. Kourembanas S, McQuillan LP, Leung GK, et al. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99-104
137. Elton TS, Oparil S, Taylor GR, et al. Normabaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992; 263: R1260-4
138. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993; 264: H150-6
139. MacArthur H, Warner TD, Wood EG, et al. Endothelin-1 release from cells in culture is elevated both acutely and chronically by short periods of mechanical stretch. Biochem Biophys Res Commun 1994; 200: 395-400
140. Morita T, Kurihara H, Maemura K, et al. Disruption of cytoskeletal structures mediates shear-stress induced endothelin-1 gene expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1706-12
141. Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties are produced by human macrophages. J Exp Med 1990; 172: 1741-8
142. Siesjo BK. Pathophysiology and treatment of focal cerebral ischaemia: part II. Mechanisms of damage and treatment. J Neurosurg 1992; 77: 337-54
143. Phillis JW. A radical view of cerebral ischaemic injury. Prog Neurobiol 1994; 42: 441-8
144. Grogaard B, Schurer L, Gerdin B, et al. Delayed hypoperfusion after incomplete forebrain ischaemia in the rat: the role of polymorphonuclear leucocytes. J Cereb Blood Flow Metab 1989; 9: 500-5
145. Dirnagl U, Niwa N, Sixt G, et al. Cortical hypoperfusion after global forebrain ischaemia in rats is not caused by microvascular plugging. Stroke 1994; 25: 1028-38
146. Tence M, Cordier J, Glowinski J, et al. Endothelin-evoked release of arachidonic acid from mouse astrocytes in primary culture. Eur J Neurosci 1992; 4: 993-9
147. Estrada V, Tellez MJ, Moya J, et al. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischaemic stroke. Am J Hypertens 1994; 7: 1085-9
148. Gallai V, Sarchielli P, Firenze C, et al. Endothelin-1 in migraine and tension type headache. Acta Neurol Scand 1994; 89: 47-55
149. Fujimori A, Yanagisawa M, Saito A, et al. Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage [letter]. Lancet 1990; 336: 633
150. Yamaura I, Tani E, Maeda Y, et al. Endothelin-1 of canine basilar artery in vasospasm. J Neurosurg 1992; 76: 99-105
151. Roux SP, Loffler B-M, Gray G, et al. The role of endothelin in experimental cerebral vasospasm. Neurosurgery 1995; 37: 78-85
152. Alafaci C, Jansen I, Arbab MA-R, et al. Enhanced vasoconstrictor effect of endothelin in the cerebral arteries from rats with subarachnoid haemorrhage. Acta Physiol Scand 1989; 138: 317-9
153. Nirei H, Hamada K, Shoubo M, et al. An endothelin (ETA) receptor antagonist FR139317 ameliorates cerebral vasospasm in dogs. Life Sci 1993; 52: 1869-74
154. Itoh S, Sasaki T, Asai A, et al. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist BQ123: change of ETA receptor mRNA expression in a canine subarachnoid haemorrhage model. J Neurosurg 1994; 81: 759-64
155. Cosentino F, McMahon EG, Carter JS, et al. Effect of endothelin A-receptor antagonist BQ123 and phosphoramidon on cerebral vasospasm. J Cardiovasc Pharmacol 1993; 22 Suppl. 8: S332-5
156. Hirose H, Ide K, Sasaki T, et al. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur J Pharmacol 1995; 277: 77-87
157. Zimmermann M, Seifert V, Stolke D, et al. Ro47-0203 prevents cerebral vasospasm after experimental subarachnoid haemorrhage [abstract]. J Cereb Blood Flow Metab 1995; 15 Suppl.: S703
158. Shigeno T, Clozel M, Sakai S, et al. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 1995; 37: 87-90
159. Willette RN, Zhang H, Mitchell MP, et al. Non peptide endothelin antagonist: cerebrovascular characterisation and effects on delayed cerebral vasospasm. Stroke 1994; 25: 2450-6
160. Miller C, Lampard DG, Alexander K, et al. Local cerebral blood flow following transient cerebral ischaemia. I. Onset of impaired reperfusion within the first hour following global ischaemia. Stroke 1980; 11: 534-41
161. Pulsinelli WA, Levy DE, Duffy TE. Regional cerebral blood flow and glucose metabolism following transient ischaemia. Ann Neurol 982; 11: 499-509
162. Frerichs KU, Siren AL, Feuerslein GZ, et al. The onset of post ischaemic hypoperfusion in rats is precipitous and may be controlled by local neurones. Stroke 1992; 23: 399-406
163. Kazda S, Gurthoff B, Krause HP, et al. Cerebrovascular effects of the calcium channel antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 1982; 32: 331-8
164. Steen PA, Newberg LA, Milde JH, et al. Cerebral blood flow and neurologic outcome when nimodipine is given after complete cerebral ischaemia in the dog. J Cereb Blood Flow Metab 1984; 4: 82-7
165. Patel TR, McCulloch J. Failure of an endothelin antagonist to modify hypoperfusion following transient global ischaemia in the rat. J Cereb Blood Flow Metab. In press
166. Smith M-L, Auer RN, Seisjo BK. The density and distribution of ischaemic brain injury in the rat following 2-10 min of forebrain ischaemia. Ada Neuropathol (Berl) 1984; 64: 319-32
167. Yamashita K, Kataoka Y, Niwa M, et al. Increased production of endothelins in the hippocampus of stroke prone spontaneously hypertensive rats following transient forebrain ischaemia: histochemical evidence. Cell Mol Neurobiol 1993; 13: 15-23
168. Feuerstein GZ, Gu J-L, Ohlstein EH, et al. Peptidic endothelin-1 receptor antagonist BQ123 and neuroprotection. Peptides 1994; 15: 467-9
169. Checkley D, Pleeth R, Breen S, et al. Effect of BQ123 on rat cerebral infarct size measured by diffusion- and T2-weighted MRI [abstract no. P174]. Proceedings of the 4th International Conference on Endothelin; 1995 Apr 23-26; London
170. Barone F, White RF, Feuerstein GZ, et al. Endothelin receptor antagonist, SB217242, reduces cerebral focal ischaemic brain injury [abstract no. P172]. Proceedings of the 4th International Conference on Endothelin; 1995 Apr 23-26; London
171. Patel JB, Wilson C. Endothelin BQ123 in the SH rat focal ischaemia model [abstract no. P173]. Proceedings of the 4th International Conference on Endothelin; 1995 Apr 23-26; London
172. Patel TR, Galbraith S, McAuley MA, et al. Increase in endothelin mediated vascular tone following focal cerebral ischaemia in the cat. J Cereb Blood Flow Metab. In press
173. A) receptor antagonists increase cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab. In press
174. Viossat I, Duverger D, Chapelat M, et al. Elevated tissue endothelin content during focal ischaemia in the rat. J Cardiovasc Pharmacol 1993; 22 Suppl. 8: S306-9
175. Brandt L, Ljunggren B, Persson K-E, et al. Effect of topical application of a calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischaemia. J Cereb Blood Flow Metab 1983; 3: 44-50
176. Date H, Hossmann KA. Effect of vasodilating drugs on intracortical and extracortical vascular resistance following middle cerebral artery occlusion in cats. Ann Neurol 1984; 16: 330-6
177. Mohammed AA, Gotoh O, Graham DI, et al. Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and metabolism and histopathology after middle cerebral artery occlusion. Ann Neurol 1985; 18: 705-11
178. Horie R, Yamori Y, Hande H. An essential difference between stroke prone SHR (SHRSP) and stroke resistant (SHRSR) rats: quantitative evidence obtained by Yamori's preparation II. Jpn Heart J 1978; 19: 630-2